Salah-Eddin Al-Batran, Prof. Dr.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Frankfurter Insitut für Klinische Krebsforschung IKF · Institut für Klinische Krebsforschung IKF GmbH
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Salah-Eddin Al-Batran, Prof. Dr. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07542678 · Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation ConceptInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · not yet recruiting · Relapsed /Refractory DLBCL · study chair
- Ph2NCT07507968 · TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal AdenocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · not yet recruiting · Esophagogastric Adenocarcinoma · study director
- Ph2NCT07176312 · Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) PatientsInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · recruiting · Gastroesophageal Adenocarcinoma, First Line Therapy, HER2 + Gastric Cancer · study director
- Ph2NCT07110038 · DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · recruiting · Penile Squamous Cell Carcinoma (PSCC) · study chair
- Ph1NCT07059299 · A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric AdenocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · recruiting · Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma
- Ph2NCT06981325 · Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) PatientsInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · recruiting · Basal Cell Carcinoma (BCC), First Line Treatment · study director
- Ph2NCT06856837 · - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver MetastasesInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · recruiting · Metastatic Colorectal Cancer · study director
- Ph2NCT06680622 · Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative ChemotherapyInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · active not recruiting · Metastatic Gastro-esophageal Adenocarcinoma
- Ph2NCT06178445 · Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract CancerInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · active not recruiting · Biliary Tract Cancer, HER2 Gene Mutation, HER2 · study chair
- N/ANCT06050434 · Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma PatientsInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · terminated · Soft Tissue Sarcoma · study director
- Ph2NCT05825625 · NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKingInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · active not recruiting · Non-small Cell Lung Cancer · study director
- Ph2NCT05798156 · Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOPInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · active not recruiting · Lymphoma, Large B-Cell, Diffuse · study chair
- Ph2NCT05713838 · Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical SurgeryInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · active not recruiting · Esophagus Adenocarcinoma · study chair
- Ph2NCT05565794 · Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/RearrangementsInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · terminated · Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation, FGFR2 Gene Rearrangement · study director
- N/ANCT05489250 · The PLATON NetworkInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · terminated · Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer · study director
- Ph2NCT05393674 · Fedratinib in Combination With NivolumabInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Primary Myelofibrosis, Secondary Myelofibrosis · study director
- Ph2NCT05268510 · Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ AdenocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Esophagogastric Adenocarcinoma · study director
- Ph2NCT05101629 · Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based TherapyInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Hepatocellular Carcinoma · study director
- Ph3NCT04803994 · The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular CarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · recruiting · Hepatocellular Carcinoma
- Ph2NCT04522544 · Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCCInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · active not recruiting · Hepatocellular Carcinoma Non-resectable, HCC · study director
- Ph2NCT04522908 · Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver FunctionInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Hepatocellular Carcinoma (HCC), Second Line Treatment · study chair
- Ph2NCT04511455 · Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line TreatmentInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma · study director
- N/ANCT04147143 · CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional StudyInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · terminated · Advanced Renal Cell Carcinoma (All Subtypes), Metastatic Renal Cell Carcinoma (All Subtypes) · study director
- N/ANCT04122872 · GISAR German Interdisciplinary Sarcoma RegistryInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · recruiting · Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone
- Ph2NCT03762564 · Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior TherapyInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Squamous Cell Carcinoma of the Esophagus · study chair
- Ph2NCT03753659 · IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Hepatocellular Carcinoma (HCC) · study director
- Ph2NCT03698227 · OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma PatientsInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · terminated · Advanced Soft Tissue Sarcoma · study director
- Ph2NCT03647969 · Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric CancerInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Adenocarcinoma of the Stomach, GastroEsophageal Cancer · study chair
- Ph2NCT03530267 · Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal CancerInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Colorectal Cancer · study chair
- Ph3NCT03520946 · RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer PatientsInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Colorectal Cancer · study chair
- N/ANCT02691052 · Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, Including a Translational ProgramInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Metastatic Pancreatic Cancer · study director
- Ph2/Ph3NCT02661971 · FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Stomach Cancer, Gastroesophageal Junction Cancer · principal investigator
- Ph2/Ph3NCT02581462 · FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ CancerInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · completed · Stomach Cancer, Gastroesophageal Junction Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in colorectal cancer.